A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : FFP / freedom from progression

[Related PubMed/MEDLINE]
Total Number of Papers: 133
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   FFP  (>> Co-occurring Abbreviation)
Long Form:   freedom from progression
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 3-Year Freedom from Progression After 68Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial. BCR, PSA, PSMA, RP, SRT
2020 Durable Complete Remission and Long-Term Survival in FDG-PET Staged Patients with Stage III Follicular Lymphoma, Treated with Wide-Field Radiation Therapy. CLI, FDG-PET, FL, TNI, WFRT
2020 Stereotactic Radiosurgery to More Than 10 Brain Metastases: Evidence to Support the Role of Radiosurgery for Ideal Hippocampal Sparing in the Treatment of Multiple Brain Metastases. CI, FFNMs, IQR, SRS, WBRT
2020 Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). CI, LC, NSCLC, OS, SBRT, SRS
2020 Treatment outcomes and prognostic analysis of elderly patients with extranodal natural killer/T-cell lymphoma, nasal type: a retrospective analysis. CR, ENKTL, OR, OS
2020 Validation of a simplified international prognostic score (IPS-3) in patients with advanced-stage classic Hodgkin lymphoma. ABVD, cHL
2019 Clinical characteristics and prognostic factors in Chinese patients with classical Hodgkin's lymphoma involving extranodal sites: a retrospective single-center. cHL, LDH, LNR, OS
2019 Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. CSI, OS, re-RT
2019 Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. 18F-FDG, CI, FL, HR, ILROG, OS, PET-CT, RT
10  2019 Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. AUC, BED, HGG, OS, PTV, SRS
11  2019 Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. 18F-FDG, FL, OS, RT
12  2019 Stereotactic Body Radiotherapy for Early-Stage Multiple Primary Lung Cancers. CI, OS, SBRT
13  2018 Multimodality Management of Recurrent Skull Base Chordomas: Factors Impacting Tumor Control and Disease-Specific Survival. DSS
14  2018 Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma. CSI, OS
15  2018 Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. cHL, NLR, PLR
16  2017 Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. ADT, ART, PSA, pT, RP
17  2017 Cesium-131 brachytherapy for recurrent brain metastases: durable salvage treatment for previously irradiated metastatic disease. Cs-131, OS, RN
18  2017 Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. PET, STV
19  2017 Clinical Outcomes of Large Brain Metastases Treated With Neurosurgical Resection and Intraoperative Cesium-131 Brachytherapy: Results of a Prospective Trial. OS, RN
20  2017 Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone? 5-PS, ABVD, eoc-PET-CT, HL, RT
21  2017 Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. OS, PPTID, PPTs
22  2017 Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma. CI, EBRT, HR, LG-NHL, OS, PTV, RIT
23  2016 Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era. CI, HL, HR, IPS, OS
24  2016 Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients. DTC, RAI, Tg
25  2016 Parameters influencing local control of meningiomas treated with radiosurgery. SRS
26  2016 Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. B2MG, cHL, HL, IPS
27  2016 Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab. DCE-US, MTT
28  2015 Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. HL, OS
29  2015 Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy. LRC, SBRT
30  2015 Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era. CT, DLBCL, LDH, OS, PET
31  2014 Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation. ASCT, HDT, IgH, MCL, MRD, OS, PCR, PFS
32  2014 Outcomes and control rates for I-125 plaque brachytherapy for uveal melanoma: a community-based institutional experience. ---
33  2014 Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastases. OS, SRS, WBRT
34  2014 Postradiotherapy CA19-9 kinetics correlate with outcomes in patients with pancreatic adenocarcinoma. CA19-9, CRT, DT, HR, OS, PORT, RT, TTN
35  2014 Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study. AUC, DCE-US
36  2013 Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. DSS, HL, IF, OS, RT
37  2013 Locoregional recurrence after preoperative radiation therapy for retroperitoneal sarcoma: adverse impact of multifocal disease and potential implications of dose escalation. DR, LRR, OS, RPS, RT
38  2013 Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation. ASCT, BEAM, FL, FLIPI, HDT
39  2013 Modeling freedom from progression for standard-risk medulloblastoma: a mathematical tumor control model with multiple modes of failure. CI, MB
40  2013 Use of image-guided stereotactic body radiation therapy in lieu of intracavitary brachytherapy for the treatment of inoperable endometrial neoplasia. AJCC, SBRT
41  2012 International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. HL, IPS, OS
42  2012 Radiotherapy alone for stage I-III low grade follicular lymphoma: long-term outcome and comparison of extended field and total nodal irradiation. EFI, OS, RR, TNI
43  2012 Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. ABVD, cHL, IPS, OS
44  2012 Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. OS, RECIST
45  2011 Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. CRPC, p-PDGFR
46  2011 Outcomes of multidisciplinary management in pediatric low-grade gliomas. GTR, NF1, OS, RT
47  2011 Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group. CI, CRu, ESR, IFRT, PR, RF, SD
48  2011 Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. GHSG, HL, OS
49  2010 Human immunodeficiency and Hodgkin lymphoma. DFS, HL, OS
50  2010 Involved-lesion radiation therapy after chemotherapy in limited-stage head-and-neck diffuse large B cell lymphoma. DLBL, HN, OS
51  2010 JC human polyomavirus is associated to chromosomal instability in peripheral blood lymphocytes of Hodgkin's lymphoma patients and poor clinical outcome. B-NHL, EBV, HL, JCV, PBL
52  2010 Long-term follow-up of dose-adapted and reduced-field radiotherapy with or without chemotherapy for central nervous system germinoma. ---
53  2010 Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. EFS, HL, MTD, OS
54  2009 Surgical resection and permanent iodine-125 brachytherapy for brain metastases. WBRT
55  2008 A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. MCL, PKCbeta
56  2008 Gamma knife radiosurgery for brainstem metastases: the UCSF experience. SRS
57  2008 Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome. EHs, HLA, MHC, NHL, SNPs
58  2008 Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma. G-CSF, NHL, OS, PFS
59  2008 Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. POH
60  2008 Radiosurgery followed by planned observation in patients with one to three brain metastases. ---
61  2008 Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation. CR, FFTM, HL, HLSS, OS
62  2007 A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. BED, CNS, Gy, RT
63  2007 Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. ---
64  2007 Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. DLBCL, PKCbeta
65  2006 Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. CR, EMZL, OALs, OS
66  2005 Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. CaPSURE, T1-3a
67  2005 Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. LPHL, NHL, OS, RT
68  2005 Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. ACC
69  2005 Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis. EFS, MCP, OS, WM
70  2005 [The role of genetic polymorphisms within tumor necrosis factor promoter gene in non-Hodgkin's lymphomas]. NHL, OS, TNF
71  2005 [The role of HLA DRB1 genetic polymorphisms in non-Hodgkin's lymphomas]. LTalpha, NHL, OS, RR, TNF
72  2004 Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. CI, DLBCL, IL-10, OS, RR
73  2004 Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. CMT, CR, CSs, CT, OS, PR, RT
74  2003 Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study. CLI, IPI
75  2003 Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients. BLM, CT, HD, I-IIA, IFRT, MTX, OS, VBL, VBM
76  2003 Gamma knife radiosurgery for recurrent salivary gland malignancies involving the base of skull. ---
77  2003 Prognostic value of GST-pi expression in diffuse large B-cell lymphomas. CR, DLBCL, GST-pi, IPI
78  2003 Prospective study of stereotactic radiosurgery without whole brain radiotherapy in patients with four or less brain metastases: incidence of intracranial progression and salvage radiotherapy. SRS, WBRT
79  2003 Radiosurgery followed by planned observation in patients with one to three brain metastases. ---
80  2003 Stage III follicular lymphoma: long-term follow-up and patterns of failure. CMT, LDH, OS
81  2002 Bone lymphoma: 67Ga scintigraphy and CT for prediction of outcome after treatment. ---
82  2002 ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. EFS, OS, VAPEC-B
83  2002 Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? CR, CSS, ECR, ER, HD, OS
84  2002 Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy. CS, CT, CTP, EFS, GP, HD, HDT, OS
85  2002 Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. IPI, LTalpha, NHL, OS, RR, TNF
86  2002 Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. OS, RT
87  2002 Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. DFS, G-CSF, HAART, IPS, OS
88  2002 The role of endorectal coil MRI in patient selection and treatment planning for prostate seed implants. EBRT, GS, MRI, PSA, RP, SI
89  2002 The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. BM, CR, Gy, LBL, OS
90  2001 Centroblastic-centrocytic non-Hodgkin's lymphoma stage I-III: patterns of failure following radiotherapy. EF-RT, IF, NHL, OAS, RFS, TLI
91  2001 Relationship between pattern of enhancement and local control of brain metastases after radiosurgery. RS
92  2000 Characteristics of 49 patients who survived for 5 years following radical radiation therapy for non-small cell lung cancer: the potential for cure. CT, NSCLC, RT
93  2000 Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience. IL-10, OS
94  2000 High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors. CR, EFS, HDCT, OS, PBSC, PR
95  1999 Radiosurgery for brain metastases: is whole brain radiotherapy necessary? CPHM, RS, WBRT
96  1999 Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation. BMT, CML, GVHD, OS, RT
97  1999 Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma. EFS, HDCT, IPI, PBSC, PR, VAPEC-B
98  1999 What is the significance of nasal involvement in nasopharyngeal carcinoma? DRALR, EP, MI, NPC
99  1998 Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages. ABVD, BuMT, CR, CS, CT, FFTM, HD, NINA, NVIS, PR
100  1997 Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. EFS, OS